Drug
Recombinant factor VIII N8 clinical trials
Also written turoctocog alfa.
How studies write it
Studies that test it under each name
Other names
Studies by the year they started
11 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2016 | 2 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses recombinant factor VIII N8 is read from its arms, and is right about nine times in ten.
Testing it · 11
- Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia ACompletedPhase 3Novo Nordisk A/SNCT01493778Written as turoctocog alfa
- Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia ACompletedPhase 3Novo Nordisk A/SNCT02938585Written as turoctocog alfa
- Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 TrialTerminatedPhase 3Novo Nordisk A/SNCT03588741Written as Turoctocog alfa
- Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks PeriodCompletedPhase 4Novo Nordisk A/SNCT03449342Written as turoctocog alfa
- Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia ACompletedPhase 1Novo Nordisk A/SNCT02941354Written as turoctocog alfa
- Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015CompletedPhase 3Novo Nordisk A/SNCT00984126Written as turoctocog alfa
- Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia ACompletedPhase 3Novo Nordisk A/SNCT01138501Written as turoctocog alfa
- Safety and Efficacy of Turoctocog Alfa in Haemophilia A SubjectsCompletedPhase 3Novo Nordisk A/SNCT00840086Written as turoctocog alfa
- A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia ACompletedPhase 1Novo Nordisk A/SNCT01365520Written as turoctocog alfa
- A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543CompletedPhase 1Novo Nordisk A/SNCT01238367Written as turoctocog alfa
- Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia ACompletedPhase 1Novo Nordisk A/SNCT01692925Written as turoctocog alfa
Given in every arm · 2 — recombinant factor VIII N8 is usual care beside what is tested
- A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without InhibitorsCompletedPhase 2Novo Nordisk A/SNCT03196297Written as Turoctocog alfa
- Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A SubjectsCompletedPhase 1Novo Nordisk A/SNCT00837356Written as turoctocog alfa
Codes
What other systems call recombinant factor VIII N8 · ClinicalTrials.gg INT006211
- RxNorm 1737557One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 1737557 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.